Investors appear more bullish than analysts despite the company's high P/E ratio, risking future disappointment if the P/E aligns with the growth outlook. The weak earnings outlook and slower market growth could risk a share price decline, threatening shareholders' investments.
诺泰生物股票讨论区
暂无评论